mAb114
E106453
mAb114 is a monoclonal antibody therapy developed to treat Ebola virus disease, shown to significantly reduce mortality during recent Ebola outbreaks.
All labels observed (1)
| Label | Occurrences |
|---|---|
| mAb114 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T903526 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: mAb114 Context triple: [2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo, treatmentUsed, mAb114]
-
A.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
B.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
-
C.
MAB
MAB is a German bibliographic data format used for cataloging and exchanging library records, closely related to and historically aligned with MARC standards.
-
D.
M1044
The M1044 is a specific armored variant of the military Humvee designed for enhanced protection and tactical utility in combat environments.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: mAb114 Target entity description: mAb114 is a monoclonal antibody therapy developed to treat Ebola virus disease, shown to significantly reduce mortality during recent Ebola outbreaks.
-
A.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
B.
rVSV-ZEBOV
rVSV-ZEBOV is an experimental recombinant vesicular stomatitis virus-based vaccine developed to protect humans against infection by the Zaire strain of the Ebola virus.
-
C.
MAB
MAB is a German bibliographic data format used for cataloging and exchanging library records, closely related to and historically aligned with MARC standards.
-
D.
M1044
The M1044 is a specific armored variant of the military Humvee designed for enhanced protection and tactical utility in combat environments.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola virus disease treatment
ⓘ
monoclonal antibody ⓘ therapeutic antibody ⓘ |
| administrationRegimen | single-dose intravenous infusion ⓘ |
| antibodyIsotype | IgG1 ⓘ |
| antibodyType | human monoclonal antibody ⓘ |
| approvalDate | 2020-12-21 ⓘ |
| approvedAs | Ebanga ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| ATCCode | J06BD09 ⓘ |
| belongsTo | Ebola virus–specific neutralizing antibodies ⓘ |
| bindsTo | Ebola virus glycoprotein ⓘ |
| clinicalTrialEvidence | PALM trial in the Democratic Republic of the Congo ⓘ |
| comparedWith |
REGN-EB3 in PALM trial
ⓘ
ZMapp in PALM trial ⓘ remdesivir in PALM trial ⓘ |
| composition | recombinant human IgG1 monoclonal antibody ⓘ |
| derivedFrom | B cells of an Ebola virus disease survivor ⓘ |
| developedBy |
National Institute of Allergy and Infectious Diseases
ⓘ
National Institute of Allergy and Infectious Diseases ⓘ
surface form:
Vaccine Research Center of NIAID
|
| developedFor | Ebola virus disease ⓘ |
| hasBrandName | Ebanga ⓘ |
| hasFullName | ansuvimab ⓘ |
| hasInternationalNonproprietaryName | ansuvimab ⓘ |
| hasPharmacologicalEffect |
improvement of survival in Ebola virus disease patients
ⓘ
reduction of Ebola virus replication ⓘ |
| hostSpecies | human ⓘ |
| indicatedFor |
treatment of Ebola virus disease in adults
ⓘ
treatment of Ebola virus disease in children ⓘ treatment of infection caused by Zaire ebolavirus ⓘ |
| indicationPopulation |
adult patients with Ebola virus disease
ⓘ
pediatric patients with Ebola virus disease ⓘ |
| isMonotherapy | true ⓘ |
| mechanismOfAction | neutralization of Ebola virus by binding viral glycoprotein ⓘ |
| origin | convalescent human donor ⓘ |
| regulatoryApproval | U.S. Food and Drug Administration approval ⓘ |
| riskCategory | treatment for life-threatening infection ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| shownTo | reduce mortality in Ebola virus disease ⓘ |
| sponsor | Ridgeback Biotherapeutics ⓘ |
| targetOrganism |
Zaire ebolavirus
ⓘ
surface form:
Zaire ebolavirus (EBOV)
|
| targets | Zaire ebolavirus ⓘ |
| therapeuticClass | antiviral monoclonal antibody ⓘ |
| usedDuring |
2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo
ⓘ
surface form:
2018–2020 Ebola outbreak in the Democratic Republic of the Congo
|
| usedIn | hospital settings ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: mAb114 Description of subject: mAb114 is a monoclonal antibody therapy developed to treat Ebola virus disease, shown to significantly reduce mortality during recent Ebola outbreaks.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.